WALTHAM, MA, TScan Therapeutics, a biopharmaceutical company, has closed an oversubscribed $100 million Series C financing. The financing round added new investors including funds and accounts managed by BlackRock, RA Capital Management, and two undisclosed healthcare-focused funds.

Existing investors including founding investor Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech also participated in the round.

TScan designs therapies that reprogram a patient's own T cells to recognize and fight their cancer using naturally occurring TCRs that recognize shared cancer targets. The TScan discovery process is a proprietary genome-wide, high-throughput target identification screen, designed to rapidly identify the natural targets of TCRs. TScan is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors.